Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756636 | 0.82 | TDP1 (0.54) | ELANETDP1ALDH1A1MAPTEP300 | |
| SCHEMBL5179538 | 0.80 | ELANE (0.59) | ELANETDP1ALDH1A1MAPTNPSR1 | |
| SCHEMBL16315749 | 0.80 | ELANE (0.59) | ELANETDP1ALDH1A1TP53MAPT | |
| SCHEMBL5789567 | 0.78 | ELANE (0.48) | ELANETDP1ALDH1A1TP53MAPT | |
| SCHEMBL3147117 | 0.77 | ELANE (0.69) | ELANETDP1ALDH1A1TP53MAPT | |
| SCHEMBL30881990 | 0.77 | ELANE (0.69) | ELANETDP1ALDH1A1TP53MAPT | |
| SCHEMBL31411806 | 0.76 | ELANE (0.55) | ELANETDP1ALDH1A1TP53MAPT | |
| SCHEMBL5789248 | 0.76 | ELANE (0.45) | ELANETDP1ALDH1A1TP53MAPT | |
| SCHEMBL13233765 | 0.76 | ELANE (0.58) | ELANETDP1ALDH1A1TP53MAPT | |
| SCHEMBL31411532 | 0.76 | ELANE (0.58) | ELANETDP1ALDH1A1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-10-26 | — | — | US | disclosed |
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | PFAHL MAGNUS | 2006-07-20 | — | — | US | disclosed |
| US-7071218-B2 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | INCYTE SAN DIEGO INCORPORATED (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1487443-A4 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1649586-A | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC (US) | 2005-08-03 | — | — | CN | disclosed |
| EP-1456187-A4 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1487443-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1456187-A1 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003075924-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003043998-A1 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, CYP46A1, PNLIP | ELANE 2394/4885TDP1 3077/4885ALDH1A1 1505/4885 |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, PC, PNLIP | ELANE 2457/4885TDP1 3347/4885ALDH1A1 1857/4885 |
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | HDAC5, KAT5, IGFBP5 | ELANE 4190/4885TDP1 4305/4885ALDH1A1 1489/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | ELANE 3992/4885TDP1 4267/4885ALDH1A1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.